Properties of ISIS 2302, an Inhibitor of Intercellular Adhesion Molecule-1, in Humans

  • W. R. ShanahanJr.
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 131)


ISIS 2302 is a 20-base phosphorothioate oligodeoxynucleotide designed to specifically hybridize to a sequence in the 3′-untranslated region of the human intercellular adhesion molecule (ICAM)-1 message. ICAM-1, a member of the immunoglobulin superfamily, is an inducible transmembrane glycoprotein constitutively expressed at low levels on vascular endothelial cells and on a subset of leukocytes (Dustin et al. 1986;Rothlein et al. 1986;Simmons et al. 1988). In response to proinflammatory mediators, many cell types upregulate expression of ICAM-1 on their surface. The primary counterligands for ICAM-1 are the β2-integrins lymphocytic function-associated antigen (LFA)-1 and macrophage differentiation antigen (Mac)-1, expressed on leukocytes (Marlin and Springer 1987;Diamond et al. 1990).


Phosphorothioate Oligonucleotide Intact Drug Acute Renal Allograft Rejection Isis Pharmaceutical Alternative Pathway Complement Activation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agrawal S, Temsamani J, Galbraith W, Tang J (1995) Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet 28(1):7–16PubMedCrossRefGoogle Scholar
  2. Allavena P, Paganin C, Martin-Padura I, Peri G, Gaboli M, Dejana E, Marchisio PC, Mantovani A (1991) Molecules and structures involved in the adhesion of natural killer cells to vascular endothelium. J Exp Med 173:439–448PubMedCrossRefGoogle Scholar
  3. Altmann DM, Hogg N, Trowsdale J, Wilkinson D (1989) Cotransfection of ICAM-1 and HLA-DR reconstitutes human antigen-presenting cell function in mouse L cells. Nature 338:512–514PubMedCrossRefGoogle Scholar
  4. Barton RW, Rothlein R, Ksiazek J, Kennedy C (1989). The effect of anti-intercellular adhesion molecule-1 on phorbol-ester-induced rabbit lung inflammation. J Immunol 143:1278–1282PubMedGoogle Scholar
  5. Bayever E, Iversen PL. Bishop MR, Sharp JG, Tewary HK, Arneson MA, Pirruccello SJ, Ruddon RW, Kessinger GZ, Armitage JO (1993) Systemic administration of phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myeloblastic leukemia and myelodysplastic syndrome: initial results of a phase I trial. Antisense Res Dev 3:383–390PubMedGoogle Scholar
  6. Bennett CF, Condon TP, Grimm S, Chan H, Chiang MY (1994) Inhibition of endothelial cell leukocyte adhesion molecule expression with antisense oligonucleotides. J Immunol 152:3530–3541PubMedGoogle Scholar
  7. Bennett CF, Kornbrust D, Henry S, Stecker K, Howard R, Cooper S, Dutson S, Hall W, Jacoby HI (1997) An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J Pharmacol Exp Ther 280:988–1000PubMedGoogle Scholar
  8. Best WR, Bectel JM, Singleton JW, Kern F (1976) Development of a Crohn’s disease activity index: National Cooperative Crohn’s Disease Study. Gastroenterology 70:439–444PubMedGoogle Scholar
  9. Best WR, Bectel JM, Singleton JW (1979) Rederived values of the eight coefficients of the Crohn’s Disease Activity Index. Gastroenterology 77:483–486Google Scholar
  10. Burke JF, Pirsch JD, Ramos EL, Salomon DR, Stablein DM, Van Buren DH, West JC (1994) Long-term efficacy and safety of cycloporine in renal-transplant patients. New Engl J Med 331:358–363PubMedCrossRefGoogle Scholar
  11. Butcher EC (1991) Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 67:1033–1036PubMedCrossRefGoogle Scholar
  12. Cecka JM, Cho YW, Terasaki PI (1992) Analysis of the UNOS scientific transplant registry at three years — early events affecting transplant success. Transplantation 53:59–64PubMedCrossRefGoogle Scholar
  13. Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bregagner JF, Florent C, Bouvry M, Mary JY, Modigliana R (1994) Correlation between clinical activity, endoscopie severity, and biological parameters in colonic or ileocolonic Crohn’s disease: a prospective multicenter study of 121 cases. Gut 35:231–235PubMedCrossRefGoogle Scholar
  14. Cosimi AB, Conti D, Delmoriico FL, Preffer FI, Wee SL, Rothlein R, Faanes R, Colvin RB (1990) In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts. J Immunol 144:4604–4612PubMedGoogle Scholar
  15. Cossum PA, Sasmor H, Dellinger D, Truong L, Cummins L, Owens SR, Markham PM, Shea JP, Crooke S (1993) Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther 267(3):1181–1190PubMedGoogle Scholar
  16. Cossum PA, Truong L, Owens SR, Markham PM, Shea JP, Crooke ST (1994) Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J Pharmacol Exp Ther 269:89–94PubMedGoogle Scholar
  17. Crooke ST, Grillone LG, Tendolkar A, Garrett A, Fratkin MJ, Leeds J, Barr WH (1994) A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital warts. Clin Pharmacol Ther 56:641–646PubMedCrossRefGoogle Scholar
  18. Diamond MS, Staunton DE, deFougerolles AR, Stacker SA, Garcia-Aguilar J, Hibbs ML, Springer TA (1990) ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/ CD18). J Cell Biol 111:3129–3139PubMedCrossRefGoogle Scholar
  19. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA (1986) Induction by IL-1 and interferon: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 137:245–254PubMedGoogle Scholar
  20. Eder PS, DeVine RJ, Dagle JM, Walder JA (1991) Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3’ exonuclease in plasma. Antisense Res Dev 1:141–151PubMedGoogle Scholar
  21. Entman ML, Youker K, Shoji T, Kukielka G, Shappell SB, Taylor AA, Smith CW (1992) Neutrophil induced oxidative injury of cardiac myocytes. J Clin Invest 90:1335–1345PubMedCrossRefGoogle Scholar
  22. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Gillies R, Hopkins M, Hanauer SB, McDonald JWD (1995) Methotrexate for the treatment of Crohn’s disease. New Engl J Med 332:292–297PubMedCrossRefGoogle Scholar
  23. Fredriksson T, Pettersson U (1978) Severe psoriasis — oral therapy with a new retinoid. Dermatologica 157:238–244PubMedCrossRefGoogle Scholar
  24. Furie MB, Tancinco MCA, Smith CW (1991) Monoclonal antibodies to leukocyte chemoattractant-stimulated neutrophil transendothelial migration in vitro. Blood 78:2089–2097PubMedGoogle Scholar
  25. Galbraith WM, Hobson, WC, Giclas PC, Schecter, PJ, Agrawal S (1994) Complement activation and hemodynamic changes following administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev 4:201–206PubMedGoogle Scholar
  26. Glover JM, Leeds JM, Mant TGK, Amin D, Kisner DL, Zuckerman JE, Geary RS, Levin AA, Shanahan WR (1997) Phase I safety and pharmacokinetic profile of an ICAM-1 antisense oligonucleotide. J Pharmacol Exp Ther 282:1173–1180PubMedGoogle Scholar
  27. Gomes P, Du Boulay C, Smith CL, Holdstock G (1986) Relationship between disease activity indices and colonoscopic findings. Gut 27:92–95Google Scholar
  28. Harning R, Pelletier J, Van G, Takel F, Merluzzi VJ (1992) Monoclonal antibody to MALA-2 (ICAM-1) reduces acute autoimmune nephritis in kdkd mice. Clin Immunol Immunopathol 64:129–134CrossRefGoogle Scholar
  29. Henry SP, Larkin R, Novotny WF, Kornbrust DJ (1994) Effects of ISIS 2302, a phosphorothioate oligonucleotide, on in vitro and in vivo coagulation parameters. Pharmaceutical Res 11:S353Google Scholar
  30. Henry SP, Taylor J, Midgley L, Levin AA, Kornbrust DJ (1997a) Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice. Antisense Nucleic Acid Drug Dev (in press)Google Scholar
  31. Henry SP, Bolte H, Auletta C, Kornbrust DJ (1997b) Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in cynomolgus monkeys. Toxicology 120:145–155CrossRefGoogle Scholar
  32. ligo Y, Takashi T, Tamatani T, Miyasaka M, Higashida T, Yagita H, Okumura K, Tsukada W (1991) ICAM-1 dependent pathway is critically involved in the pathogenesis of adjuvant arthritis in rats. J Immunol 147(12):4167–4171PubMedGoogle Scholar
  33. Isobe M, Yagita H, Okumura K, Ihara A (1992) Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 255:1125–1127PubMedCrossRefGoogle Scholar
  34. Kahan BD (1993) Toward a rationale design of clinical trials of immunosuppressive agents in transplantation. Immunol Rev 136:29–49PubMedCrossRefGoogle Scholar
  35. Kawasaki K, Yaoita E, Yamamoto T, Tamatani T, Miyasaka M, Kihara I (1993) Antibodies against intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 prevent glomerular injury in rat experimental crescentic glomerulonephritis. J Immunol 150(3):1074–1083PubMedGoogle Scholar
  36. Kelly KJ, Williams WW, Colvin RB, Bonventre JB (1994) Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury. Proc Natl Acad Sci USA 91:812–816PubMedCrossRefGoogle Scholar
  37. Kuhlman P, Moy VT, Lollo BA, Brian AA (1991) The accessory function of murine intercellular adhesion molecule-1 in T lymphocyte activation. J Immunol 146:1773–1782PubMedGoogle Scholar
  38. Kumasaka T, Quinlan WM, Doyle NA, Condon TP, Sligh J, Takei F, Beaudet AL, Bennett CF, Doerschuk CM (1996) The role of ICAM-1 in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice. J Clin Invest 97:2362–2369PubMedCrossRefGoogle Scholar
  39. Lacy MJ, Voss EW (1989) Direct adsorption of ssDNA to polystyrene for characterisation of the DNA/anti-DNA interaction and immunoassay for anti-DNA autoantibody in New Zealand White mice. J Immunol Methods 116:87–98PubMedCrossRefGoogle Scholar
  40. Leeds JM, Graham MJ, Truong L, Cummins LL (1996) Quantitation of phosphorothioate oligonucleotides in human plasma. Anal Biochem 235:36–43PubMedCrossRefGoogle Scholar
  41. Liang H, Nishioka Y, Reich CF, Pisetsky DS, Lipsky PE (1996) Activation of human B cells by phosphorothioate oligodeoxynucleotides. J Clin Invest 98:1119–1129PubMedCrossRefGoogle Scholar
  42. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S (1994) Cyclosporine in severe ulcerative colitis refractory to steroid therapy. New Engl J Med 330:1841–1845PubMedCrossRefGoogle Scholar
  43. Ma XI, Lefer DJ, Lefer AM, Rothlein R (1992) Coronary endothelial and cardiac protective effects of a monoclonal antibody to intercellular adhesion molecule-1 in myocardial ischemia and reperfusion. Circulation 86:937–946PubMedCrossRefGoogle Scholar
  44. Makgoba MW, Sanders ME, Luce GEG, Gugel EA, Dustin TL, Springer TA, Shaw S (1988) Functional evidence that intercellular adhesion molecule-1 (ICAM-1) is a ligand for LFA-1-dependent adhesion in T cell-mediated cytotoxicity. Eur J Immunol 18:637–640PubMedCrossRefGoogle Scholar
  45. Marlin SD, Springer TA (1987) Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen-1 (LFA-1). Cell 51:813–819PubMedCrossRefGoogle Scholar
  46. Mary JY, Modigliani R (1989) Development and validation of a Crohn’s disease endoscopie index: a prospective multicentric study. Gut 30:983–989PubMedCrossRefGoogle Scholar
  47. McCabe RP, Woody S, Van Deventer S, Targan SR, Mayer L, Van Hogezand R, Rutgeerts P, Hanauer SB, Podolsky D, Elson CO (1996) A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn’s disease. Gastroenterology 110 [Suppl 4]:A962Google Scholar
  48. Mielo ME, Bennett CF, Miller BE, Welch DR (1994) Enhanced metastatic ability of TNF-a treated malignant melanoma cells is reduced by intercellular adhesion molecule-1 (CD54) antisense oligonucleotides. Exp Cell Res 214:231–241CrossRefGoogle Scholar
  49. Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, Rene E (1990) Clinical, biological, and endoscopie picture of attacks of Crohn’s disease: evolution on prednisolone. Gastroenterology 98:811–818PubMedCrossRefGoogle Scholar
  50. Monteith DK, Henry SP, Howard RB, Flournoy S, Levin AA, Bennett CF, Crooke ST (1997) Immune stimulation — a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des 12:421–432PubMedGoogle Scholar
  51. Nestle F, Mitra RS, Bennett CF, Nickoloff BJ (1994) Cationic lipid is not required for uptake and inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotide in keratinocytes. J Invest Dermatol 103:569–575PubMedCrossRefGoogle Scholar
  52. Oppenheimer-Marks N, Davis LS, Bogue DT, Ramberg J, Lipsky PE (1991) Differential utilization of ICAM-1 and VCAM-1 during the adhesion and transendothelial migration of human T lymphocytes. J Immunol 147:2913–2921PubMedGoogle Scholar
  53. Paulus HE, Egger MJ, Ward JR, Williams HJ (1990) Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatie drugs, based on the findings in patients treated with placebo. Arthritis Rheum 33:477–484PubMedCrossRefGoogle Scholar
  54. Rothlein R, Dustin ML, Marlin SD, Springer TA (1986) A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol 137:1270–1274PubMedGoogle Scholar
  55. Scheynius A, Camp RL, Pure E (1993) Reduced contact sensitivity reactions in mice treated with monoclonal antibodies to leukocyte function-associated molecule-1 and intercellular adhesion molecule-1. J Immunol 150(2):655–663PubMedGoogle Scholar
  56. Simmons D, Makgoba MW, Seed B (1988) ICAM, an adhesion ligand of LFA-1, is homologous to the neural cell adhesion molecule NCAM. Nature 331:624–627PubMedCrossRefGoogle Scholar
  57. Springer TA (1990) The sensation and regulation of interactions with the extracellular environment: the cell biology of lymphocyte adhesion receptors. Annu Rev Cell Biol 6:359–401PubMedCrossRefGoogle Scholar
  58. Statistical Consultants Inc (1986) PCNONLIN and NONLIN84: software for the statistical analysis of nonlinear models. Am Stat 40:52Google Scholar
  59. Stepkowski SM, Tu Y, Condon TP, Bennett CF (1994) Blocking of heart allograft rejection by ICAM-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities. J Immunol 153:5336–5346PubMedGoogle Scholar
  60. Targan SR, Rutgeerts P, Hanauer SB, Van Deventer SJH, Mayer L, Present DH, Braakman TAJ, Woody JN (1996) A multicenter trial of anti-tumor necrosis factor (TNF) antibody (cA2) for treatment of patients with active Crohn’s disease. Gastroenterology 110 [Suppl 4j:A1026Google Scholar
  61. Truelove SC, Witts LJ (1959) Cortisone and corticotrophin in ulcerative colitis. Br Med J i:387–394CrossRefGoogle Scholar
  62. Van Deventer SJH, Elson CO, Fedorak RN (1996) Safety, tolerance, pharmacokinetics and pharmacodynamics of recombinant interleukin-10 (SCH 52000) in patients with steroid refractory Crohn’s disease. Gastroenterology 110 Suppl 41:A1034Google Scholar
  63. Wegner CD, Gundel RH, Reilly P, Haynes N, Letts LG, Rothlein R (1990) Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma. Science 247:456–459PubMedCrossRefGoogle Scholar
  64. Williams CM (1988) Transplant rejection: an overview from the clinical perspective. In: Meryman HT (ed) Transplantation: approaches to graft rejection. Proceedings of the 18th annual session of the American Red Cross. Liss, New YorkGoogle Scholar
  65. Yacyshyn B, Woloschuk B, Yacyshyn MB, Martini D, Doan K, Tami J, Bennett F, Kisner D, Shanahan W (1997) Efficacy and safety of ISIS 2302 (ICAM-1 antisense oligonucleotide) treatment of steroid-dependent Crohn’s disease. Gastroenterology 112:A1123Google Scholar
  66. Zhang R, Yan J, Shahinian H, Amin G, Lu Z, Liu T, Saag MS, Jiang Z, Temsamani J, Martin RR, Schechter PJ, Agrawal S (1995) Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin Pharmacol Ther 58:44–53SPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • W. R. ShanahanJr.

There are no affiliations available

Personalised recommendations